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ORIGINAL ARTICLE
Prevalence and molecular epidemiology of Clostridium difficile infection in
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Abstract
Clostridium difficile has not been studied in detail in Asia, particularly Southeast Asia. We thus performed a prevalence study across four
hospitals in Central Java province, Indonesia. Stool samples were collected from patients with diarrhoea and tested by enzyme
immunoassay for glutamate dehydrogenase (GDH) and toxin A/B (C DIFF QUIK CHEK COMPLETE, TechLab). Specimens were cultured
and molecular typing was performed. In total, 340 samples were tested, of which 70 (20.6%) were GDH positive, with toxin detected in
19 (5.6%). Toxigenic C. difficile was isolated from 37 specimens (10.9%), while a further 36 (10.6%) nontoxigenic isolates were identified.
The most common strain was ribotype 017 (24.3% of 74 isolates), followed by nontoxigenic types QX 224 (9.5%), and QX 238 and QX
108 (both 8.1%). The high prevalence of C. difficile highlights a need for ongoing surveillance of C. difficile infection in Indonesia.
© 2017 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.
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Clostridium difficile causes hospital- and community-acquired
infections ranging in severity from self-limiting diarrhoea to
life-threatening toxic megacolon and pseudomembranous coli-
tis. The main risk factors for C. difficile infection (CDI) are
recent antimicrobial exposure, hospitalization, residence in a
healthcare facility and advanced age [1].
The symptoms of CDI are mediated by toxins A (entero-
toxin) and B (cytotoxin), encoded by the genes tcdA and tcdB
respectively [2]. A third binary toxin, CDT, is encoded by the
genes cdtA and cdtB, which are found less frequently than tcdA
and tcdB [2]. Toxigenic strains cause disease, always carry tcdB
and generally tcdA and less frequently produce binary toxin;
however, asymptomatic colonization with toxigenic strains is
also possible. Nontoxigenic strains do not carry tcdA and tcdB;
nor do they cause disease. Therefore, detection of C. difficile
alone is insufficient to diagnose CDI because toxin A and/or B
must be detected in stool and diarrhoea must be present [3].
PCR detection of tcdB can identify toxigenic C. difficile but will
not distinguish colonization from infection.
Recent major outbreaks of CDI in North America and
Europe were attributed to a binary toxin-positive (A+B+CDT+)
strain of C. difficile (ribotype (RT) 027) [4]. Outbreaks caused by
this strain have highlighted the need for worldwide surveillance
of CDI and causative strains. The relatively few reports about
C. difficile from Asia show a predominance of a toxin A–
negative toxin B–positive (A−B+) strain, RT 017, while CDT+
strains are rare [5]. However, the limited investigations of CDI
in Asia, particularly Southeast Asia [5], may have given an
incomplete picture. Other diarrhoea-causing pathogens are
more commonly tested for as a result of poor awareness of
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CDI among Asian physicians [6]. In addition, limited resources
mean diagnostic tests for CDI are often lacking or inadequate.
For example, in a study from the Philippines, patients with CDI
were incorrectly diagnosed with amoebiasis [7]. In addition,
some studies of CDI performed in the early 2000s used enzyme
immunoassays (EIAs) for toxin A to detect C. difficile, which
likely resulted in underdiagnosis of CDI, given the high pro-
portion of RT 017 strains in Asia [5].
There are very few reports on CDI in Indonesia. A preva-
lence of 1.3% by toxin A EIA was reported in community and
hospital clinics in Jakarta in 1999 [8], and eight Indonesian
strains of C. difficile isolated from healthy individuals, six of
which were A−B+, were described in 1993 [9]. Reports of
inappropriate antibiotic prescribing [10] and free access to
antibiotics without prescriptions suggest that CDI may be
common in Indonesia. Therefore, we aimed to investigate the
prevalence and molecular epidemiology of CDI in hospital in-
patients in Indonesia.
Methods
This prospective study was conducted from July 2014 to
February 2015 in four hospitals in Central Java province, as
follows: site 1, Semarang, 1070 beds; site 2, Jepara, 420 beds;
site 3, Purwokerto, 730 beds; and site 4, Semarang, 240 beds.
Diarrhoeal (loose or watery) stool specimens were tested at all
sites by EIA for glutamate dehydrogenase (GDH) and toxin A/B
using C DIFF QUIK CHEK COMPLETE (TechLab, USA). GDH-
positive specimens were sent to Western Australia on trans-
port swabs in Cary-Blair medium (Medical Wire & Equipment
Co. Ltd., UK) for culture and molecular analysis. Culture, PCR
ribotyping and toxin gene detection of C. difficile were per-
formed as previously described [11].
Results
In total, 340 samples were tested, of which 19 (5.6%) were
GDH positive/toxin positive. A further 51 (15.0%) were GDH
positive/toxin negative (Table 1). C. difficile was not recovered
by culture from four specimens, two of which were toxin
positive. Eight specimens yielded two unique isolates, resulting
in isolation of 74 unique C. difficile strains. A tcdB-positive
C. difficile strain was isolated from 20 toxin-negative specimens.
Overall, 38 unique strains were tcdB positive, with two isolated
from the same specimen, giving a prevalence of toxigenic
C. difficile of 37 (10.9%) of 340. Six other specimens yielded one
toxigenic and one nontoxigenic strain each. The overall prev-
alence of nontoxigenic C. difficile was 36 (10.6%) of 340. The
most common toxigenic strain was RT 017 (A−B+, n = 18,
24.3% of isolates), then QX 134 (A−B+, n = 3, 4.1%), RT 053
and QX 215 (both A+B+, n = 3, 4.1%). Nontoxigenic types QX
224 (n = 7, 9.5%), QX 238 and QX 108 (n = 6, both 8.1%) were
also common (Table 2). No CDT+ strains were identified.
Discussion
The prevalence of C. difficile in Indonesia was relatively high
compared to neighbouring countries. While Australia (7.2%
toxigenic C. difficile) [12] has a prevalence comparable to many
developed countries, Singapore (7–11% toxin positive) [13] and
Malaysia (13.7%) [14] had higher prevalence by toxin EIA, a
relatively insensitive test. A recent study in Thailand identified
similar high proportions of toxigenic (9.2%) and nontoxigenic
C. difficile (15.6%) among 422 patients with diarrhoea [11].
The high prevalence of C. difficile in Indonesia, a country with
widespread inappropriate antibiotic usage, is concerning. Until
TABLE 1. Results of EIA and culture analysis in Indonesian inpatients
EIA result Culture Toxin profile
Site, n (%)
1 (n [ 148) 2 (n [ 98) 3 (n [ 49) 4 (n [ 45) Total (n [ 340)
GDH+/Toxin+ Positive A+B+CDT− 1 (0.7) 0 2 (4.1) 1 (2.2) 4 (1.2)
A−B+CDT− 12 (8.1) 1 (1.0) 0 0 13 (3.8)
A−B−CDT− 4 (2.7)a 1 (1.0)a 0 0 5 (1.5)a
Negative 1 (0.7)a 1 (1.0) 0 0 2 (0.6)a
GDH+/Toxin− Positive A+B+CDT− 6 (4.1) 0 5 (10.2) 1 (2.2) 12 (3.5)b
A−B+CDT− 6 (4.1) 2 (2.0) 0 1 (2.2) 9 (2.6)
A−B−CDT− 10 (6.8)c 9 (9.2) 9 (18.4) 3 (6.7) 31 (9.1)c
Negative 1 (0.7) 1 (1.0) 0 0 2 (0.6)
Negative 112 (75.7) 84 (85.7) 35 (71.4) 39 (86.7) 271 (79.5)
EIA, enzyme immunoassay; GDH, glutamate dehydrogenase.
aFive specimens contained one toxigenic and one nontoxigenic strain.
bOne specimen contained two distinct toxigenic strains.
cTwo specimens contained one toxigenic and one nontoxigenic strain.
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recently, limited resources made CDI diagnostics inadequate,
and anaerobic culture facilities facilitating molecular analysis
were lacking, making surveillance difficult; however, culture
facilities and molecular typing were recently established at site 1
(Dr Kariadi Hospital). It would be beneficial to carry out sur-
veillance to monitor infection rates and movement of strains,
and expand on the findings of this study.
One limitation of our study was that the prevalence may
have been underestimated because GDH-negative samples,
some of which may have been falsely negative, were not
cultured. Furthermore, given ongoing debates about diagnosis
of CDI [3], it is difficult to determine how many tcdB-positive
patients were colonized and how many had a true infection.
The predominant molecular type in our study, RT 017
(Table 2), is commonly found throughout Asia, including China
[5], and particularly in neighbouring Thailand [11] and Singapore
[15]. The low prevalence of CDT+ isolates is in line with pre-
vious Asian studies [5]. The high prevalence of nontoxigenic
strains of C. difficile was interesting, and further studies should
explore the role of such strains in Southeast Asia. Colonization
with a nontoxigenic strain of C. difficile protects against colo-
nization with other potentially virulent strains of C. difficile [16],
and this may be occurring in Asia leading to lower rates of
disease. The identification of molecular types which are
frequently found in neighbouring countries supports the need
for surveillance of international spread of C. difficile strains.
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